Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02206-17. doi: 10.1128/AAC.02206-17. Print 2018 May.


The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR Bacteroides spp. and Clostridium difficile Eravacycline was potent in vitro against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam-β-lactamase inhibitor combinations.

Keywords: Bacteroides; anaerobes; antimicrobial resistance; eravacycline.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteria, Anaerobic / drug effects*
  • Drug Resistance, Bacterial
  • Microbial Sensitivity Tests
  • Tetracyclines / pharmacology*


  • Anti-Bacterial Agents
  • Tetracyclines
  • eravacycline